Wednesday, August 17, 2005 10:38:25 PM
In general, under Rule 144 as amended, a person who has beneficially owned and held "restricted" securities for at least one year, including "affiliates," may sell publicly without registration under the Securities Act, within any three-month period, assuming compliance with other provisions of the Rule, a number of shares that do not exceed the greater of (i) one percent of the common stock then outstanding or, (ii) the average weekly trading volume in the common stock during the four calendar weeks preceding such sale. A person who is not deemed an "affiliate" of our Company and who has beneficially owned shares for at least two years would be entitled to unlimited resales of such restricted securities under Rule 144 without regard to the volume and other limitations described above.
As of December 31, 2003, there were 5,300,000 shares of common stock that are considered restricted securities under Rule 144 of the Securities Act of 1933. All 5,300,000 shares are held by Jamie Kerr and John Shaffer, both of whom are our affiliates, as that term is defined in Rule 144(a)(1). At the present time, the resale or transfer of the restricted shares of Common Stock held by Messrs. Kerr and Shaffer is not permissible because both affiliates have entered into a "lock-up" agreement, whereby their holdings may not be sold until the earlier of the following events:
1. A period of three years from, December 1, 2003, the effective date of the offering conducted under Rule 504 of Regulation D (which date shall be December 1, 2006),
2. When our stock is traded on the OTCBBr at an average share price of greater than $0.025 per share for a minimum of three months,
3. Our shares are listed on the Nasdaq SmallCap MarketSM or higher market or
4. We have paid the purchasing shareholders in the Regulation D offering their investment in the form of cash dividends.
As these events have not yet occurred, Messrs. Kerr and Shaffer may not divest themselves of their ownership in our company, neither through public or private means.
Has any of these happened yet ? I dont think so ..So the shares are still restricted right? Its only beeb trading since 7/18/2005
As of December 31, 2003, there were 5,300,000 shares of common stock that are considered restricted securities under Rule 144 of the Securities Act of 1933. All 5,300,000 shares are held by Jamie Kerr and John Shaffer, both of whom are our affiliates, as that term is defined in Rule 144(a)(1). At the present time, the resale or transfer of the restricted shares of Common Stock held by Messrs. Kerr and Shaffer is not permissible because both affiliates have entered into a "lock-up" agreement, whereby their holdings may not be sold until the earlier of the following events:
1. A period of three years from, December 1, 2003, the effective date of the offering conducted under Rule 504 of Regulation D (which date shall be December 1, 2006),
2. When our stock is traded on the OTCBBr at an average share price of greater than $0.025 per share for a minimum of three months,
3. Our shares are listed on the Nasdaq SmallCap MarketSM or higher market or
4. We have paid the purchasing shareholders in the Regulation D offering their investment in the form of cash dividends.
As these events have not yet occurred, Messrs. Kerr and Shaffer may not divest themselves of their ownership in our company, neither through public or private means.
Has any of these happened yet ? I dont think so ..So the shares are still restricted right? Its only beeb trading since 7/18/2005
Recent FITY News
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • GlobeNewswire Inc. • 01/05/2026 06:08:59 PM
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • InvestorsHub NewsWire • 01/05/2026 06:00:00 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • GlobeNewswire Inc. • 10/09/2025 02:23:35 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • InvestorsHub NewsWire • 10/09/2025 02:00:00 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • GlobeNewswire Inc. • 09/30/2025 01:56:45 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • InvestorsHub NewsWire • 09/30/2025 01:45:00 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • GlobeNewswire Inc. • 09/23/2025 01:07:25 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • InvestorsHub NewsWire • 09/23/2025 12:35:36 PM
- Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Global Oncology Data Through AI-Driven Real-World Evidence • InvestorsHub NewsWire • 09/04/2025 12:30:00 PM
- Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032 • InvestorsHub NewsWire • 08/26/2025 01:00:00 PM
- Fifty1 Labs, Inc. Subsidiary Fifty1 AI Labs Partners with ViRx@Stanford Under 'BE READI!' Initiative to Advance AI-Powered Antiviral Drug Repurposing • InvestorsHub NewsWire • 08/22/2025 02:30:00 PM
- Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation • InvestorsHub NewsWire • 08/12/2025 12:30:00 PM
- Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference, Showcasing AI-Driven Functional Medicine Strategy and World-Class Leadership • InvestorsHub NewsWire • 07/29/2025 01:00:00 PM
- Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières • InvestorsHub NewsWire • 07/28/2025 12:30:00 PM
- Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies • InvestorsHub NewsWire • 07/17/2025 12:30:00 PM
- Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • InvestorsHub NewsWire • 07/10/2025 12:30:49 PM
- Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • InvestorsHub NewsWire • 07/08/2025 12:30:00 PM
- Fifty 1 Labs, Inc. Accelerates Growth with New CEO, BioSentry Division Launch and Shareholder Dividend; Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness • InvestorsHub NewsWire • 04/30/2025 12:32:59 PM
- UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV • InvestorsHub NewsWire • 04/09/2025 01:00:00 PM
